- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03022630
Palliative Care for Non-Malignant Diseases (COMPASS Trial) (COMPASS)
The Creation of Models for Palliative Assessments to Support Severe Illness (COMPASS) Investigation: Testing Early and Ongoing Implementation of Palliative Care for Incurable Non-malignant Diseases
Study Overview
Status
Intervention / Treatment
Detailed Description
Palliative care is specialized medical care focused on providing patients with relief from the symptoms, pain, and stress of serious or life-limiting illness, regardless of diagnosis, by anticipating, preventing, and treating suffering. Palliative care aims to provide patients and their families with services to help patients make the best possible medical decisions in the face of serious illness. Unfortunately it is often thought to be synonymous with hospice care and therefore underutilized as a part of standard care. Patients with chronic liver disease or cirrhosis may be a particularly underserved population for palliative care, as palliative care may be disregarded until hope of liver transplantation is lost.
Study Description:
- Adult patients admitted to Vanderbilt University Medical Center with cirrhotic advanced liver disease and poor prognosis will be randomized to receive either usual hepatic care or usual hepatic care with comprehensive palliative care services.
- Participants randomized to the intervention arm will receive patient-friendly informational materials, a comprehensive initial palliative care consultation, and follow-up consultations while inpatient. After discharge from hospital, follow-up consults will occur via telephone contact. Telephone contacts will occur on a flexible schedule based on needs and wishes of the participant at a minimum frequency of one contact per month.
- Participants will receive the palliative care intervention for at least 1 year after randomization to the intervention arm or until death.
- Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a meeting is requested by the patient, the family, or treating physician. These consultations include the same palliative care services as the intervention arm, excluding the telephone follow-up consultations.
- All participants will complete quality of life, mood, and satisfaction with care assessments at specified time points for 1 year after randomization or until death. Optional caregiver participation includes completion of satisfaction with care assessments.
Specific aims include:
- Assess the impact of systematic, comprehensive palliative care services compared to usual hepatic care on time to first hospital readmission within 1-year post randomization.
- Assess the impact of systematic, comprehensive palliative care services compared to usual hepatic care on other hospital utilization, including days alive out of hospital within 6- months post randomization, total days in hospital (and ICU) within 1-year post randomization, number and cost of hospital admissions within 1-year post randomization, median length of stay per admission, transfers and time to hospice placement, and survival within 1-year post randomization.
- Assess the impact of systematic, comprehensive palliative care services compared to usual hepatic care on qualify of life.
- Assess the impact of systematic, comprehensive palliative care services compared to usual hepatic care on patient/caregiver satisfaction.
- Evaluate the fidelity of the palliative care intervention and assess the generalizability of implementing a large-scale Palliative Care program.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Inpatient at Vanderbilt University Medical Center with advanced cirrhotic liver disease, whose treating hepatologist indicates a 'No' response to the question, "Would you be surprised if this patient died within 1 year?"
Exclusion Criteria:
- Age < 18 years
- Receipt of liver transplant at the time of potential enrollment
- Inability to give written informed consent (patient or surrogate decision-maker)
- Inability to respond to questions in English
- Treating hepatologist denies permission to enroll
- Receiving hepatology care at non-Vanderbilt sites (to ensure appropriate follow-up)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Comprehensive Palliative Care services
Comprehensive Palliative Care services in addition to usual hepatic care
|
Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care.
If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact.
Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month.
If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures.
If the participant is readmitted, the consultation schedule will restart.
|
|
Other: Usual hepatic care
|
Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician.
These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to First Hospital Readmission Within 6 Months Post-randomization
Time Frame: 6 months post-randomization
|
Assess the impact of palliative care services on time to first hospital readmission. Time frame was changed from 1 year to 6 months due to early termination. |
6 months post-randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Days Alive Out of Hospital
Time Frame: 6 months post-randomization
|
Days alive out of hospital from randomization to 6 months post randomization compared across arms. Time frame was changed from 1 year to 6 months due to early termination. |
6 months post-randomization
|
|
Total Days in Hospital
Time Frame: 6 months post-randomization
|
Total days in hospital from randomization to 6 months post randomization compared across arms Time frame was changed from 1 year to 6 months due to early termination.
|
6 months post-randomization
|
|
Total Days in ICU
Time Frame: 6 months post-randomization
|
Total days in ICU from randomization to 6 months post randomization compared across arms. Time frame was changed from 1 year to 6 months due to early termination. |
6 months post-randomization
|
|
Number of Hospital Readmissions
Time Frame: 6 months post-randomization
|
Number of hospital readmissions from randomization to 6 months post randomization compared across arms. Time frame was changed from 1 year to 6 months due to early termination. |
6 months post-randomization
|
|
Median Length of Hospital Stay Per Admission
Time Frame: 6 months post-randomization
|
Median length of hospital stay per admission from randomization to 6 months post randomization compared across arms. Time frame was changed from 1 year to 6 months due to early termination. |
6 months post-randomization
|
|
Hospice Referral
Time Frame: 6 months post-randomization
|
Number of transfers to hospice within 6 months post randomization compared across arms. Time frame was changed from 1 year to 6 months due to early termination. |
6 months post-randomization
|
|
Time to Hospice Placement
Time Frame: 6 months post-randomization
|
Number of days from hospice referral to time to hospice placement.
Time frame was changed from 1 year to 6 months due to early termination.
There are only 3 patients with a hospice admission date that is after baseline discharge, all of whom are from the control group.
The remaining patients with hospice referral but are missing a hospice admission date due to death before hospice admission.
Therefore, it is not feasible to calculate any statistics.
|
6 months post-randomization
|
|
Change in Chronic Liver Disease Questionnaire (CLDQ)
Time Frame: Change from baseline over 6 months post-randomization
|
Change in liver disease-related quality of life: The CLDQ is a 29-item questionnaire measuring 6 domains. Item scores range from 1 to 7 with higher scores indicating better quality of life. The total score can range from 29 to 203 with a score of 1 meaning the symptom being assessed is "present always" while a score of 7 means the symptom is "never present". Therefore, a higher score corresponds to a better quality of life while a lower score corresponds to a worse quality of life. The questions in each domain have a range of factor loads indicative of their impact, and a clinically important difference is defined as a score change of 0.5. Time frame was changed from 1 year to 6 months due to early termination. |
Change from baseline over 6 months post-randomization
|
|
Change in EQ-5D-5L
Time Frame: Change from baseline over 6 months post-randomization
|
Change in generic health status: The EQ-5D-5L is a 5-item questionnaire with responses ranging from absence of symptom to extreme experience of the symptom. This scale is numbered from 0 to 100. 100 means the best health you can imagine and 0 means the worst health you can imagine. Time frame was changed from 1 year to 6 months due to early termination. |
Change from baseline over 6 months post-randomization
|
|
Change in PROMIS Emotional Distress - Anxiety - Short Form 4a
Time Frame: Change from baseline over 6 months post-randomization
|
Change in mood (anxiety): The PROMIS Emotional Distress - Anxiety - Short Form 4a contains 4 items that measure anxiety on a 5-point Likert scale with higher scores indicating increased symptomatology. The raw score can range from 4 to 20 which converts to a t-score range of 40.3 to 81.6. Time frame was changed from 1 year to 6 months due to early termination. |
Change from baseline over 6 months post-randomization
|
|
Change in PROMIS Emotional Distress - Depression - Short Form 4a
Time Frame: Change from baseline over 6 months post-randomization
|
Change in mood (depression): The PROMIS Emotional Distress - Depression - Short Form 4a contains 4 items that measure depression on a 5-point Likert scale with higher scores indicating increased symptomatology. The raw score ranges from 4 to 20 which converts to a t-score range of 41.0 to 79.4. Time frame was changed from 1 year to 6 months due to early termination. |
Change from baseline over 6 months post-randomization
|
|
Change in Satisfaction With Care (Quality of End-of-Life Care: Questionnaire for Patient)
Time Frame: Change from baseline over 6 months post-randomization
|
Change in patient satisfaction with care: The Quality of End-of-Life Care: Questionnaire for Patient is an 11-item questionnaire, with items scored on a 10-point Likert type scale with higher scores indicating better satisfaction with care. The score can range from 0 to 110. Time frame was changed from 1 year to 6 months due to early termination. |
Change from baseline over 6 months post-randomization
|
|
Change in Kingston Caregiver Stress Scale
Time Frame: Change from baseline over 6 months post-randomization
|
The Kingston Caregiver Stress Scale will be used to measure caregiver stress. The KCSS is designed to measure stress experienced by lay caregivers, not institutional staff, and was designed to monitor change in an individuals stress over time. Ten items are grouped into three categories: care giving, family, and financial issues. Scores can range from 10 to 50. Lower scores indicate less stress and higher scores indicate high stress. Time frame was changed from 1 year to 6 months due to early termination. |
Change from baseline over 6 months post-randomization
|
|
Change in Satisfaction With Care (Quality of End-of-Life Care: Questionnaire for Patient Adapted for Caregiver)
Time Frame: Change from baseline over 6 months post-randomization
|
Change in caregiver satisfaction with care: The Quality of End-of-Life Care: Questionnaire for Patient item wording was modified to apply to caregivers. The questionnaire is an 11-item questionnaire, with items scored on a 10-point Likert type scale with higher scores indicating better quality of care. The score can range from 0 to 110. Time frame was changed from 1 year to 6 months due to early termination. |
Change from baseline over 6 months post-randomization
|
|
Liver Transplant Status
Time Frame: 6 months post-randomization
|
Number of deferred, listed, and declined listing for liver transplant compared across arms. Time frame was changed from 1 year to 6 months due to early termination. Liver transplant status data was not obtained. |
6 months post-randomization
|
|
Model for End-Stage Liver Disease (MELD) Score
Time Frame: Baseline
|
Baseline MELD score compared across arms.
MELD score ranks the participants degree of sickness and indicates how much the participant needs a liver transplant.
The score ranges from 6-40.
The higher the number the more urgent the need for a transplant.
|
Baseline
|
|
Completed Liver Transplants
Time Frame: 6 months post-randomization
|
Number of patients with completed liver transplants compared across arms.
Time frame was changed from 1 year to 6 months due to early termination.
|
6 months post-randomization
|
|
Physical Symptoms
Time Frame: 6 months post-randomization
|
Number of documented physical symptoms (ascites, variceal bleeding, encephalopathy, etc.) compared across arms. Time frame was changed from 1 year to 6 months due to early termination. Physical symptom data was not obtained. |
6 months post-randomization
|
|
Presence of Advance Directives
Time Frame: 6 months post-randomization
|
Percentage of patients with documented advance care directives compared across arms. Time frame was changed from 1 year to 6 months due to early termination. |
6 months post-randomization
|
|
Survival
Time Frame: 6 months post-randomization
|
Survival rate compared across arms.
Time frame was changed from 1 year to 6 months due to early termination.
|
6 months post-randomization
|
|
Provider Satisfaction
Time Frame: Change from Baseline to study closeout.
|
The "ICU Provider Satisfaction Survey with the Palliative Care Program:Veterans Affairs of Ann Arbor" instrument is available online and has been modified for the current study by removing the 'ICU' reference and revising 'pain' to symptoms more relevant to the current population. The survey includes 7-item questionnaire, with items scored on a 5-point Likert type scale with higher scores indicating better provider satisfaction. The score can range from 0 to 35. Time frame was changed due to early termination. Data was not collected. |
Change from Baseline to study closeout.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 160746
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
Foundation for the National Institutes of HealthRecruitingLiver Fat | Cirrhosis, Liver | Liver Fibrosis | NASH | Liver Inflammation | Metabolic Associated Fatty Liver Disease | Liver Steatoses | Metabolic Associated Steatotic Liver DiseaseUnited States
-
Tehran University of Medical SciencesNot yet recruitingLiver Transplant; Complications | Liver Transplant Disorder | End-stage Liver DiseaseIran, Islamic Republic of
-
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE...RecruitingLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Metastases | Liver Cancer | Liver Transplant Rejection | Liver SteatosesChina
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Medical University of WarsawNot yet recruitingEnd Stage Liver Disease | Liver Transplantation | Liver Transplant | Liver Transplant SurgeryPoland
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Shengjing HospitalEnrolling by invitationLiver Steatosis | Liver Fibrosis | Liver Fibrosis Progression in Chronic Liver Disease | Steatotic Liver Disease | Steatotic Liver Disease of Mixed Origin (MetALD)China
-
Taipei City HospitalThe One Biopharmaceutical Co., Ltd.CompletedNon-alcoholic Fatty Liver Disease | Liver Fibrosis | Liver InjuryTaiwan
Clinical Trials on Comprehensive Palliative Care services
-
Vietnam Palliative Health Care SocietyUniversity Medical Center Ho Chi Minh City (UMC)CompletedQuality of Life | Psychological Distress | Advanced CancerVietnam
-
McMaster UniversityUnknownPalliative Care | Satisfaction | Primary CareCanada
-
Istituto Romagnolo per lo Studio dei Tumori Dino...CompletedCancer | Chronic Obstructive Pulmonary Disease | Idiopathic Pulmonary Fibrosis | Chronic Renal FailureItaly
-
Hospices Civils de LyonCompletedAcute Leukaemia in RelapseFrance
-
University of ChicagoNorthwestern University; University of Illinois at Chicago; Rush University Medical... and other collaboratorsActive, not recruitingMedicare Patients | High Risk of HospitalizationsUnited States
-
Hunter College of City University of New YorkNational Center for Advancing Translational Sciences (NCATS)Recruiting
-
Seoul National University HospitalRecruitingCritical IllnessKorea, Republic of
-
Dartmouth-Hitchcock Medical CenterAmerican Cancer Society (ACS)RecruitingAdvanced Cancer | Metastatic Cancer (Different Solid Tumour Types) | Palliative Care, Health Services | Palliative Care ReferralUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Atrium Health Wake Forest BaptistRecruitingCancer | Chemotherapy | FrailUnited States
-
Centre Hospitalier Emile RouxRecruiting